Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate Efficacy and Safety of IBI112 in Adolescent Participants With Moderate to Severe Plaque Psoriasis
Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD.
Summary
The purpose of this study is to evaluate the efficacy and safety of IBI112 in the treatment of adolescent participants with moderate to severe plaque-type psoriasis.
Official title: A Phase Ⅰ/Ⅲ Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Picankibart in Adolescent Patients With Moderate to Severe Plaque Psoriasis
Key Details
Gender
All
Age Range
12 Years - 18 Years
Study Type
INTERVENTIONAL
Enrollment
104
Start Date
2025-12-03
Completion Date
2029-01-31
Last Updated
2025-12-22
Healthy Volunteers
No
Conditions
Interventions
IBI112
IBI112 by subcutaneous injection
placebo
placebo by subcutaneous injection
Locations (1)
Beijing Children's Hospital Affiliated to Capital Medical University
Beijing, Beijing Municipality, China